Pfizer exceeds fourth-quarter expectations but starts 2023 with low forecast

Covid-19 booster vaccines and treatments for coronavirus helped push Pfizer to a better-than-expected final quarter of 2022 (Mark Lennihan/AP)

Covid-19 booster vaccines and treatments for coronavirus helped push Pfizer to a better-than-expected final quarter of 2022.

However, the pharmaceutical giant announced on Tuesday a 2023 forecast that starts off well below Wall Street forecasts.